about
Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease.Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant.Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome.Recurrent atypical haemolytic uraemic syndrome post kidney transplant due to a CD46 mutation in the setting of SMARCAL1-mediated inherited kidney disease.The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia.A protocol for the identification and validation of novel genetic causes of kidney diseaseMutations in mitochondrial DNA causing tubulointerstitial kidney disease.Fibrillary glomerulonephritis: An apparent familial form?KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease.KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis.KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling.KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management.KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care.KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease.KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease.End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.Genomics in the renal clinic - translating nephrogenetics for clinical practiceThe increasing rates of acute interstitial nephritis in Australia: a single centre case series.End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases.Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders.Renal Genetics in Australia: Kidney Medicine in the Genomic AgeParaneoplastic immunoglobulin A nephropathy and associated focal segmental glomerulosclerosis in asymptomatic low volume B-cell lymphoma - a case reportSustained remission of systemic lupus erythematosus related calciphylaxisGenetic analyses of medication-use and implications for precision medicinePatient-iPSC-Derived Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and Reveal Underlying Pathogenetic MechanismsGenome-wide association study of medication-use and associated disease in the UK BiobankNOS3 as a potential modifier of ADPKD phenotypic variability: progress towards an answerThe Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, AustraliaADPedKD: A Global Online Platform on the Management of Children With ADPKDAntenatally Diagnosed ADPKDCFHR5 Nephropathy in a Greek-Cypriot Australian Family: Ancestry-Informed Precision MedicineTreatment and long-term outcome in primary distal renal tubular acidosisComprehensive evaluation of a prospective Australian patient cohort with suspected genetic kidney disease undergoing clinical genomic testing: a study protocolIsolated proteinuria due to CUBN homozygous mutation - challenging the investigative paradigmPilot clinical and validation study of the PROPKD score in clinical practice amongst patients with Autosomal Dominant Polycystic Kidney Disease
P50
Q30203008-539DD6B0-4DB7-436C-A502-DF1E619065F0Q33412869-980676F2-8B6B-4F8A-99B2-23AEB1B6AEC6Q33424946-81B8AE7F-CD1B-466A-A6AF-ED2518EEE7B4Q33439114-3D61003B-CC65-404A-A3B2-ABAB22621C5CQ33439122-783BE3EF-75CB-4DD0-9402-A875BEE6C029Q33858105-8034EEFA-7A49-46CB-A113-FD2639E0544DQ35776875-742A6C65-F948-4505-B221-10FDEC6C773AQ36299446-81CB692A-E0CE-4C34-8C84-927623CAE06FQ38524439-E001A322-B5BD-4A3F-B308-07E1493455FEQ38618900-67644EA6-0C4F-40FB-B38A-A398FA25AB82Q38618900-EE6D5447-8A02-4982-ABB4-DEC33FED0DA6Q38683257-EF0C7F6C-FE8D-430C-8777-6E904715CDEAQ38683259-1979DAEC-0F89-46E0-9682-8B187D062456Q38683270-52D56938-74ED-4B9D-B928-C9426F011BA5Q38683273-D6C3F715-396E-4FD3-99D1-EAD9CBA6E59EQ38683279-749111EE-0E51-4008-AE9E-E8254514C939Q38683287-1E18108D-7BF4-4613-9B50-BDC7B14826C0Q40486596-90B4173F-0220-4CE9-8BCD-05E4A34D70F9Q40805918-32E96E88-B986-440E-9A19-622556268CBFQ45219814-F5EC05ED-C2D5-4358-B74B-F9F20F2EBEDEQ51125064-4B27108F-8827-4906-906B-C1F87E60278FQ54060993-69FE5E55-C10A-4674-8878-22E208EE1EF9Q57153302-03F78F97-2CD8-438F-AE35-47C98D18603EQ58755809-88F5618B-48AF-4494-BDF5-4B1BE99BAB48Q58887637-463B4CF4-2826-465A-916F-B9037A39B7BFQ60405801-7C615626-4DB4-4C08-9D08-C7FDF84EA229Q60638389-4C7FEFAC-C1AF-47A7-AD06-2D5C63908D6FQ63433278-7057478B-31F0-46BE-8851-EFB333A9C3C3Q86003596-46026B4E-ED03-427E-A057-711AECD53CDDQ89842428-CC9B99B9-40D9-4AF4-9CCA-F8D7A284AF11Q90089710-FCF1A36E-A885-4F3F-8129-6C7DD2E69D81Q91350029-2528B484-F413-49BB-BA49-D41B0410F18BQ91350038-2D02B054-B47E-4973-8536-F9E80B2B48A4Q91657653-DB5D1B22-4B8E-436E-A2C2-340022B48FCCQ92430472-2EFC6419-DB07-4386-8C2F-D367AF4E0AC3Q92786626-083691EE-97AD-417D-BF1B-7926891742B7Q92807038-B631D7F7-96BA-4E5C-8B3C-EA3EC2C6F761
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrew Mallett
@ast
Andrew Mallett
@en
Andrew Mallett
@es
Andrew Mallett
@nl
Andrew Mallett
@sl
type
label
Andrew Mallett
@ast
Andrew Mallett
@en
Andrew Mallett
@es
Andrew Mallett
@nl
Andrew Mallett
@sl
prefLabel
Andrew Mallett
@ast
Andrew Mallett
@en
Andrew Mallett
@es
Andrew Mallett
@nl
Andrew Mallett
@sl
P106
P21
P31
P496
0000-0002-8752-2551